Marc Goodman
Stock Analyst at Leerink Partners
(2.93)
# 1,364
Out of 4,829 analysts
96
Total ratings
53.12%
Success rate
26.97%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $4.60 | +117.39% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $110.16 | +36.17% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.40 | +151.07% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $20.56 | +191.83% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $29.37 | +8.95% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $61.99 | -59.67% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $14.80 | +237.84% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $9.98 | +100.40% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $120.43 | -4.51% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $124.40 | +149.20% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $9.59 | +25.13% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $35.85 | +28.31% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $17.52 | +19.86% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $103.58 | +102.74% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $6.75 | +492.59% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.63 | +513.50% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $31.27 | -13.66% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $2.21 | +578.73% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $412.38 | -34.53% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $190.07 | -49.49% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.18 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $80.43 | -16.70% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $26.99 | +263.10% | 7 | Oct 5, 2017 |
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $4.60
Upside: +117.39%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $110.16
Upside: +36.17%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.40
Upside: +151.07%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $20.56
Upside: +191.83%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $29.37
Upside: +8.95%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $61.99
Upside: -59.67%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $14.80
Upside: +237.84%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $9.98
Upside: +100.40%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $120.43
Upside: -4.51%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $124.40
Upside: +149.20%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $9.59
Upside: +25.13%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $35.85
Upside: +28.31%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $17.52
Upside: +19.86%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $103.58
Upside: +102.74%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $6.75
Upside: +492.59%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.63
Upside: +513.50%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $31.27
Upside: -13.66%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $2.21
Upside: +578.73%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $412.38
Upside: -34.53%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $190.07
Upside: -49.49%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $48.18
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $80.43
Upside: -16.70%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $26.99
Upside: +263.10%